Pyrrolo-1,5-benzoxazepine-15 (PBOX-15) is a novel microtubule depolymerization agent that induces cell cycle arrest and subsequent apoptosis in a number of cancer cell lines. Chronic lymphocytic leukemia (CLL) is characterized by clonal expansion of predominately nonproliferating mature B cells. Here, we present data suggesting PBOX-15 is a potential therapeutic agent for CLL. We show activity ...

Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in Western countries. There are approximately 19 000 new cases diagnosed in the United States in 2016 (https://seer. cancer.gov/statfacts/html/clyl.html). MicroRNAs (miRs) have been implicated as one of the key contributors in the pathogenesis of CLL. One of these miRNAs is miR-155, which is probably the bestcharacterized ...

Background: Phenylketonuria as the most common genetic metabolic disorder is the result of disruption of the phenylalanine hydroxylase gene. This study was carried out to explore the phenylalanine hydroxylase gene mutation status of Iranian phenylketonuria patients.    Methods: Blood samples were collected from 30 patients, and hot spot areas of the phenylalanine hydroxylase gene, in...

Ferrajoli and colleagues present the results of a phase 2 study in which lenalidomide was administered by continuous daily dosing to 44 patients with relapsed CLL. Clinical activity (ORR 32%, CR 7%) was observed, and responses were seen in patients with poor-risk cytogenetic abnormalities and unmutated IgVH. However, the mechanism(s) of action and the optimal dosing schedule of lenalidomide rem...

Background Myeloproliferative disorders are a group of diseases characterized by increased proliferation of myeloid lineage. In addition to JAK2V617F mutation, several mutations in the c-MPL gene were described in patients with Philadelphia-negative chronic myeloproliferative disorders that could be important in the pathogenesis of diseases. The aim of present study was to investigate the fre...

Introduction:B-cell chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease with many patients surviving for decades with watch and wait strategy or no treatment, whereas others surrender to their disease despite therapy. In recent years, new molecular prognostic factors came to light that have significantly improved the stratification of the CLL patients. One of the most impor...